- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
EXACT Sciences Corporation (EXAS)
EXACT Sciences Corporation stock price live, this page displays NASDAQ EXAS stock exchange data. View the EXAS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the EXACT Sciences Corporation real time stock price chart below.
What Is the EXACT Sciences Corporation Stock Price Today?
The EXACT Sciences Corporation stock price today is 103.24.
What Is the Stock Symbol for EXACT Sciences Corporation?
The stock symbol for EXACT Sciences Corporation is "EXAS."
What Stock Exchange Does EXACT Sciences Corporation Trade On?
EXACT Sciences Corporation is listed and trades on the NASDAQ stock exchange.
Is EXACT Sciences Corporation a Good Stock to Buy?
Determining whether EXACT Sciences Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EXAS quote. (ISIN: US30063P1057)
What Is the EXACT Sciences Corporation Stock Price Today?
The EXACT Sciences Corporation stock price today is 103.24.
What Is the Stock Symbol for EXACT Sciences Corporation?
The stock symbol for EXACT Sciences Corporation is "EXAS."
What Stock Exchange Does EXACT Sciences Corporation Trade On?
EXACT Sciences Corporation is listed and trades on the NASDAQ stock exchange.
Is EXACT Sciences Corporation a Good Stock to Buy?
Determining whether EXACT Sciences Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EXAS quote. (ISIN: US30063P1057)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
103.15
103.43
52 wk Range
38.81
103.54
EXAS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
103.15103.43
52 wk Range
38.81103.54
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EXAS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
105.81
Upside
+2.49%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High return over the last year
- Exact Sciences Co receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Exact Sciences stock hits 52-week high at $102.69
- Investing.com
- Exact Sciences stock hits 52-week high at $102.69
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
EXACT Sciences Corporation Company Profile
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
EXACT Sciences Corporation Earnings Call Summary for Q3/2025
- Exact Sciences reported Q3 2025 EPS of $0.24, surpassing forecasted loss of $0.03, with revenue of $851M exceeding expectations by 5.02% and growing 20% year-over-year.
- The company raised full-year revenue guidance to $3.22-3.235B and targets 15% compound annual growth rate from 2022-2027, with long-term goal of 20% adjusted EBITDA margins.
- Screening revenue rose 22% to $666M while precision oncology revenue increased 12% to $183M, driving a 37% rise in adjusted EBITDA to $135M.
- Free cash flow improved to $190M, up $77M from previous year, with stock price increasing 0.42% in aftermarket trading following the earnings announcement.
- CEO Kevin Conroy emphasized focus on cancer eradication through early detection, with expansion plans including international growth and investment in technologies like OncoDetect and MRD.
Last Updated: 2025-11-03, 06:28 p/m
Read Full TranscriptCompare EXAS to Peers and Sector
Metrics to compare | EXAS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEXASPeersSector | |
|---|---|---|---|---|
P/E Ratio | −94.8x | 9.1x | −0.5x | |
PEG Ratio | −1.18 | −0.04 | 0.00 | |
Price/Book | 8.2x | 3.5x | 2.6x | |
Price / LTM Sales | 6.1x | 7.0x | 3.3x | |
Upside (Analyst Target) | 1.7% | 289.0% | 47.1% | |
Fair Value Upside | Unlock | 11.3% | 5.8% | Unlock |
Analyst Ratings
3 Buy
19 Hold
0 Sell
Ratings:
22 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 105.81
(+2.49% Upside)
Earnings
Latest Release
Feb 13, 2026
EPS / Forecast
-- / -0.0808
Revenue / Forecast
-- / 860.90M
People Also Watch
FAQ
What Is the EXACT Sciences (EXAS) Stock Price Today?
The EXACT Sciences stock price today is 103.24
What Stock Exchange Does EXACT Sciences Trade On?
EXACT Sciences is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for EXACT Sciences?
The stock symbol for EXACT Sciences is "EXAS."
What Is the EXACT Sciences Market Cap?
As of today, EXACT Sciences market cap is 19.71B.
What Is EXACT Sciences's Earnings Per Share (TTM)?
The EXACT Sciences EPS (TTM) is -1.10.
When Is the Next EXACT Sciences Earnings Date?
EXACT Sciences will release its next earnings report on May 13, 2026.
From a Technical Analysis Perspective, Is EXAS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has EXACT Sciences Stock Split?
EXACT Sciences has split 0 times.
How Many Employees Does EXACT Sciences Have?
EXACT Sciences has 7150 employees.
What is the current trading status of EXACT Sciences (EXAS)?
As of Feb 16, 2026, EXACT Sciences (EXAS) is trading at a price of 103.24, with a previous close of 103.23. The stock has fluctuated within a day range of 103.15 to 103.43, while its 52-week range spans from 38.81 to 103.54.
What Is EXACT Sciences (EXAS) Price Target According to Analysts?
The average 12-month price target for EXACT Sciences is USD105.81, with a high estimate of USD118 and a low estimate of USD105. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +2.49% Upside potential.
What Is the EXAS Premarket Price?
EXAS's last pre-market stock price is 103.16. The pre-market share volume is 540.00, and the stock has decreased by -0.07, or -0.07%.
What Is the EXAS After Hours Price?
EXAS's last after hours stock price is 103.10, the stock has decreased by -0.14, or -0.14%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.